Practical aspects in the diagnosis and management of aplastic anemia

American Journal of the Medical Sciences

Volumn 313, Issue 3, 1997, Pages 159-169

  Fonseca, Rafael ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bone marrow transplantation; Diagnosis; Immunosuppressive therapy; Outcome; Survival rate

Indexed keywords

APLASTIC ANEMIA; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CLINICAL PRACTICE; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; PATHOGENESIS; RECURRENT DISEASE; REVIEW; SURVIVAL; TREATMENT PLANNING;

EID: 0030893461     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199703000-00007     Document Type: Review

References (184)

1. International Agranulocytosis and Aplastic Anemia Study. The incidence of aplastic anemia: The relevance of diagnostic criteria. Blood. 1987;70:1718-21.
2. Szklo M, Sensenbrenner L, Markowitz J, Weida S, Warm S, Linet M. Incidence of aplastic anemia in metropolitan Baltimore: A population-based study. Blood. 1985;66:115-9.
3. Issaragrisil S, Sriratanasatavorn C, Piankijagum A, Vannasaeng S, Porapakkham Y, Leaverton PE, et al. Incidence of aplastic anemia in Bangkok. The Aplastic Anemia Study Group. Blood. 1991;77:2166-8.
4. Yang C, Zhang X. Incidence survey of aplastic anemia in China. Chin Meet Sci J. 1991;6:203-7.
5. Young NS, Alter BP. Aplastic Anemia: Acquired and Inherited. Philadelphia: W.B. Saunders Company; 1994;24,171.
6. Issaragrisil S, Kaufman DW, Young NS for the Aplastic Anemia Study Group. The epidemiology of acquired aplastic anemia (AA) in Thailand (abstract). Blood. 1995;86(suppl 1):478a.
7. Issaragrisil S, Kaufman DW, Anderson TE, Chansung K, Thamprasit T, Sirijirachai J, et al. An association of aplastic anaemia in Thailand with low socioeconomic status. Aplastic Anemia Study Group. Br J Haematol. 1995;91:80-4.
8. Hotta T, Kato T, Maeda H, Yamao H, Yamada H, Saito H. Functional changes in marrow stromal cells in aplastic anaemia. Acta Haematol. 1985;74:65-9.
9. Holmberg LA, Seidel K, Leisenring W, Torok-Storb B. Aplastic anemia: Analysis of stromal cell function in long-term marrow cultures. Blood. 1994;84:3685-90.
10. Marsh JC, Chang J, Testa NG, Hows JM, Dexter TM. In vitro assessment of marrow 'stem cell' and stromal cell function in aplastic anaemia. Br J Haematol. 1991;78:258-67.
11. Frickhofen N, Liu JM, Young NS. Etiologic mechanisms of hematopoietic failure. American Journal of Pediatric Hematology/Oncology. 1990;12:385-95.
12. van Kamp H, Landegent JE, Willemze R, Fibbe WE. Patients with aplastic anemia (AA) before or after treatment with anti-thymocyte globulin (ATG) may exhibit clonal hematopoiesis. Bone Marrow Transplant. 1991;7(suppl 2):99.
13. Josten KM, Tooze JA, Borthwick-Clarke C, Gordon-Smith EC, Rutherford TR. Acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria: Studies on clonality. Blood. 1991;78:3162-7.
14. Anan K, Ito M, Misawa M, Ohe Y, Kai S, Kohsaki M, et al. Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgon-receptor (HUMARA) gene. Br J Haematol. 1995;89:838-44.
15. Mathe G, Amiel JL, Schwarzenberg L, Choay J, Trolard P, Schneider M, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 1970;2:131-6.
16. Young N, Griffith P, Brittain E, Elfenbein G, Gardner F, Huang A, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood. 1988;72:1861-9.
17. Camitta BM, Doney K. Immunosuppressive therapy for aplastic anemia: Indications, agents, mechanisms, and results. Am J Pediatr Hematol Oncol. 1990;12:411-24.
18. Novitzky N, Wood L, Jacobs P. Treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone. Am J Hematol. 1991;36:227-34.
19. Nakao S, Yamaguchi M, Shiobara S, Yokoi T, Miyawaki T, Taniguchi T, et al. Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood. 1992;79:2532-5.
20. Zoumbos NC, Gascon P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985;312:257-65.
21. Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci USA. 1985;82:188-92.
22. Hinterberger W, Adolf G, Aichinger G, Dudczak R, Geissler K, Höcker P, et al. Further evidence for lymphokine overproduction in severe aplastic anemia. Blood. 1988;72:266-72.
23. Fuchs D, Denz HA, Nachbauer D, Reibnegger G, Wachter H. Circulating gamma-interferon in patients with aplastic anemia (letter). Blood. 1989;73:858-9.
24. Nistico A, Young NS. Gamma-interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1994;120:463-9.
25. Schultz JC, Shahidi NT. Detection of tumor necrosis factor-alpha in bone marrow plasma and peripheral blood plasma from patients with aplastic anemia. Am J Hematol. 1994;45:32-8.
26. Gascon P, Zoumbos NC, Scala G, Djeu JY, Moore JG, Young NS. Lymphokine abnormalities in aplastic anemia: Implications for the mechanism of action of antithymocyte globulin. Blood. 1985;65:407-13.
27. Viale M, Merli A, Bacigalupo A. Analysis at the clonal level of T-cell phenotype and functions in severe aplastic anemia patients. Blood. 1991;78:1268-74.
28. Maciejewski JP, Hibbs JR, Anderson S, Katevas P, Young NS. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol. 1994;22:1102-10.
29. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245-52.
30. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528-30.
31. Callera F, Garcia AB, Falcao RP. Increased Fas antigen expression on lymphocytes from severe aplastic anemia (abstract). Blood. 1995;86(suppl 1):478a.
32. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-γ constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood. 1996;87:4149-57.
33. Dhodapkar MV, Lust JA, Phyliky RL. T-cell large granular lymphocytic leukemia and pure red cell aplasia in a patient with type I autoimmune polyendocrinopathy: Response to immunosuppressive therapy. Mayo Clin Proc. 1994;69:1085-8.
34. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: A T-cell clonopathy of undetermined significance? Blood. 1994;84:1620-7.
35. Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: A descriptive clinical study. Blood. 1994;84:2721-5.
36. Guiguet M, Baumelou E, Mary JY. A case-control study of aplastic anaemia: Occupational exposures. The French Cooperative Group for Epidemiological Study of Aplastic Anaemia. Int J Epidemiol. 1995;24:993-9.
37. Gibson FM, Marsh JC, Gordon-Smith EC. In vitro revelations of aplastic anemia. International Journal of Cell Cloning. 1992;10:262-8.
38. Kaufman DW, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York: Oxford University Press; 1991.
39. Yardley-Jones A, Anderson D, Parke DV. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. British Journal of Industrial Medicine. 1991;48:437-44.
40. Wallerstein RO, Condit PK, Kasper CK, Brown JW, Morrison FR. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA. 1969;208:2045-50.
41. Nagao T, Mauer AM. Concordance for drug-induced aplastic anemia in identical twins. N Engl J Med. 1969;281:7-11.
42. Robins MM. Aplastic anemia secondary to anticonvulsants. American Journal of Diseases in Children. 1962;104:614-24.
43. Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: The controversy. Epilepsia. 1991;32(suppl 5):S74-9.
44. Felbamate linked to aplastic anemia; warning issued on drug's use. Am J Hosp Pharm. 1994;51:2324.
45. Cameron A, Eisen AA, Niranjan LM. Aplastic anaemia due to phenylbutazone. Postgrad Med J. 1966;42:49-51.
46. McCarthy DD, Chalmers TM. Hematological complications of phenylbutazone therapy: Review of the literature and report of two cases. Can Med Assoc J. 1964;90:1061-7.
47. Hansen RM, Csuka ME, McCarty DJ, Saryan LA. Gold induced aplastic anemia. Complete response to corticosteroids, plasmapheresis, and N-acetylcysteine infusion. J Rheumatol. 1985;12:794-7.
48. McSweeney PA, Carter JM, Green GJ, Romeril KR. Fatal aplastic anemia associated with hepatitis B viral infection. Am J Med. 1988;85:255-6.
49. Domenech P, Palomeque A, Martinez-Gutierrez A, Vinolas N, Vela E, Jimenez R. Severe aplastic anaemia following hepatitis A. Acta Haematol. 1986;76:227-9.
50. Nissen C. The pathophysiology of aplastic anemia. Semin Hematol. 1991;28:313-8.
51. Zeldis JB, Dienstag JL, Gale RP. Aplastic anemia and non-A, non-B hepatitis. Am J Med. 1983;74:64-8.
52. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-62.
53. Pant A, Kale P, Harjai K, Shah M, Pathare AV. Non-A non-B hepatitis induced aplastic anemia. J Postgrad Med. 1992;38:85-6.
54. Hagler L, Pastore RA, Bergin JJ, Wrensch MR. Aplastic anemia following viral hepatitis: Report of two fatal cases and literature review. Medicine (Baltimore). 1975;54:139-64.
55. Pol S, Thiers V, Driss F, Devergie A, Berthelot P, Brechot C, et al. Lack of evidence for a role of HCV in hepatitis-associated aplastic anaemia. Br J Haematol. 1993;85:808-10.
56. Hibbs JR, Issaragrisil S, Young NS. High prevalence of hepatitis C viremia among aplastic anemia patients and controls from Thailand. Am J Trop Med Hyg. 1992;46:564-70.
57. Hibbs JR, Frickhofen N, Rosenfeld SJ, Feinstone SM, Kojima S, Bacigalupo A, et al. Aplastic anemia and viral hepatitis. Non-A, Non-B, Non-C? JAMA. 1992;267:2051-4.
58. Böttiger LE, Westerholm B. Aplastic anaemia. 3. Aplastic anaemia and infectious hepatitis. Acta Med Scand. 1972;192:323-6.
59. Pikis A, Kavaliotis J, Manios S. Incidence of aplastic anemia in viral hepatitis in children. Scand J Infect Dis. 1988;20:109-10.
60. Tzakis AG, Arditi M, Whitington PF, Yanaga K, Esquivel C, Andrews WA, et al. Aplastic anemia complicating orthotopic liver transplantation for non-A, non-B hepatitis. N Engl J Med. 1988;319:393-6.
61. Spivak JL, Bender BS, Quinn TC. Hematologic abnormalities in the acquired immune deficiency syndrome. Am J Med. 1984;77:224-8.
62. Samuel D, Castaing D, Adam R, Saliba F, Chamaret S, Misset JL, et al. Fatal acute HIV infection with aplastic anaemia, transmitted by liver graft (letter). Lancet. 1988;1:1221-2.
63. Spitzer TR, Farhi DC, Lederman M. Aplastic anemia, malignant lymphoma, and the acquired immunodeficiency syndrome (letter). N Engl J Med. 1987;317:1289-90.
64. Lazarus KH, Baehner RL. Aplastic anemia complicating infectious mononucleosis: A case report and review of the literature. Pediatrics. 1981;67:907-10.
65. Shadduck RK, Winkelstein A, Zeigler Z, Lichter J, Goldstein M, Michaels M, et al. Aplastic anemia following infectious mononucleosis: Possible immune etiology. Exp Hematol. 1979;7:264-71.
66. Baranski B, Armstrong G, Truman JT, Quinnan GV Jr, Straus SE, Young NS. Epstein-Barr virus in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1983;109:695-704.
67. Purtilo DT, Sakamoto K, Barnabei V, Seeley J, Bechtold T, Rogers G, et al. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): Update on studies of the registry. Am J Med. 1982;73:49-56.
68. Hoffman R, Dainiak N, Sibrack L, Pober JS, Waldron JA Jr. Antibody-mediated aplastic anemia and diffuse fasciitis. N Engl J Med. 1979;300:718-21.
69. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988;17:221-31.
70. Pajor A, Kelemen E, Szakacs Z, Lehoczky D. Pregnancy in idiopathic aplastic anemia (report of 10 patients). Eur J Obstet Gynecol Reprod Biol. 1992;45:19-25.
71. Matloub YH, Brunning RD, Arthur DC, Ramsay NK. Severe aplastic anemia preceding acute lymphoblastic leukemia. Cancer. 1993;71:264-8.
72. Fleming LE, Timmeny W. Aplastic anemia and pesticides. An etiologic association? Journal of Occupational Medicine. 1993;35:1106-16.
73. Gordon-Smith EC, Rutherford TR. Fanconi anaemia - constitutional, familial aplastic anaemia. Baillieres Clin Haematol. 1989;2:139-52.
74. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi Anemia Registry: Relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989;73:391-6.
75. Yabe M, Yabe H, Matsuda M, Hinohara T, Oh Y, Hattori K, et al. Bone marrow transplantation for Fanconi anemia. Adjustment of the dose of cyclophosphamide for preconditioning. American Journal of Pediatric Hematology/Oncology. 1993;15:377-82.
76. Young NS. The problem of clonality in aplastic anemia: Dr. Dameshek's riddle, restated. Blood. 1992;79:1385-92.
77. Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med. 1991;325:991-6.
78. van Kamp H, van Imhoff GW, de Wolf JT, Smit JW, Halie MR, Vellenga E. The effect of cyclosporine on haematological parameters in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;89:79-82.
79. Rayson D, Kang EM, Inwards DJ. 27-Year-old woman with pancytopenia. Mayo Clin Proc. 1995;70:185-8.
80. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology. 1995;45:456-60.
81. Brown KE, Green SW, Wong S, Sferra TJ, Fishbein M, Desai SM, et al. A novel hepatitis virus implicated in the etiology of hepatitis/aplasia syndrome and seronegative fulminant hepatitis (abstract). Blood. 1995;86(suppl 1):585a.
82. Banks AT, Piatick M, Jeffers LJ, Bernstein DE, Schiff ER, Kim J, et al. Hepatitis G virus related aplastic anemia (abstract). Blood. 1995;86(suppl 1):479a.
83. Gordon MY. Physiology and function of the haemopoietic microenvironment. Br J Haematol. 1994;86:241-3.
84. Gordon MY, Gordon-Smith EC. Bone marrow fibroblastoid colony-forming cells (F-CFC) in aplastic anaemia: Colony growth and stimulation of granulocyte-macrophage colony-forming cells (GM-CFC). Br J Haematol. 1981;49:465-77.
85. Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood. 1995;86:3277-86.
86. Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol. 1995;23:81-7.
87. Tuzuner N, Cox C, Rowe JM, Bennett JM. Bone marrow cellularity in myeloid stem cell disorders: Impact of age correction. Leuk Res. 1994;18:559-64.
88. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, et al. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. Int J Hematol. 1993;58:53-61.
89. Kampmeier P, Anastasi J, Vardiman JW. Issues in the pathology of the myelodysplastic syndromes. Hematology/Oncology Clinics of North America. 1992;6:501-22.
90. Tichelli A, Gratwohl A, Nissen C, Signer E, Stebler Gysi C, Speck B. Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin. Blood. 1992;80:337-45.
91. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, et al. Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48:63-70.
92. Weinberger M. Approach to management of fever and infection in patients with primary bone marrow failure and hemoglobinopathies. Hematol Oncol Clin North Am. 1993;7:865-85.
93. Storb R, Thomas ED, Buckner CD, Clift RA, Deeg HJ, Fefer A, et al. Marrow transplantation in thirty "untransfused" patients with severe aplastic anemia. Ann Intern Med. 1980;92:30-6.
94. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. Blood. 1989;73:606-13.
95. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84:1703-21.
96. Nissen C, Gratwohl A, Speck B. Management of aplastic anemia. Eur J Haematol. 1991;46:193-7.
97. Grumet FC, Yankee RA. Long-term platelet support of patients with aplastic anemia. Effect of splenectomy and steroid therapy. Ann Intern Med. 1970;73:1-7.
98. Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion. The selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med. 1969;281:1208-12.
99. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995;85:3367-77.
100. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297-304.
101. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood, 1995;85:3058-65.
102. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood. 1995;85:1348-53.
103. Matloub YH, Smith C, Bostrom B, Smithson WA, Priest J, Koerper MA, et al. Comparison of one versus two courses of antithymocyte globulin (ATG) for the treatment of severe aplastic anemia in children (abstract). Blood 1995;86(suppl 1):479a.
104. Cunningham E, Chi Y, Brentjens J, Venuto R. Acute serum sickness with glomerulonephritis induced by antithymocyte globulin. Transplantation. 1987;43:309-12.
105. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984;311:1407-13.
106. Bielory L, Gascon P, Lawley TJ, Young NS, Frank MM. Human serum sickness: A prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine (Baltimore). 1988;67:40-57.
107. Rossi SJ, Schroeder TJ, Hariharan S, First MR. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf. 1993;9:104-31.
108. Sanchez-Valle E, Morales-Polanco MR, Gomez-Morales E, Gutierrez-Alamillo LI, Gutierrez-Espindola G, Pizzuto-Chavez J. Tratamiento de la hemoglobinuria paroxistica nocturna con globulina antilinfocitaria. Rev Invest Clin. 1993;45:457-61.
109. Batiuk TD, Bennett WM, Norman DJ. Cytokine nephropathy during antilymphocyte therapy. Transplant Proc. 1993:25(suppl 1):27-30.
110. Dykewicz MS, Rosen ST, O'Connell MM, Patterson R, Kuzel TM, Gilyon KA. Plasma histamine but not anaphylatoxin levels correlate with generalized urticaria from infusions of anti-lymphocyte monoclonal antibodies. J Lab Clin Med. 1992;120:290-6.
111. Bielory L, Wright R, Nienhuis AW, Young NS, Kaliner MA. Antithymocyte globulin hypersensitivity in bone marrow failure patients. JAMA. 1988;260:3164-7.
112. Russ GR. Complications of immunosuppressive therapy in transplantation. 2: Specific immunosuppressive agents. Med J Aust. 1992;157:264-7.
113. Billett HH. Aplastic anemia: The role of immunosuppression. Hosp Pract. 1992;27:35-40.
114. Huang AT, Mold NG. The role of CD45RO in antithymocyte globulin's stimulation of primitive haemopoietic cells. Br J Haematol. 1994;88:643-6.
115. Doolittle GC, Bodensteiner DC, Skikne BS, Amare M. Therapy of aplastic anemia with sequential antithymocyte globulin and cyclosporin. Am J Hematol. 1991;36:144-6.
116. Tong J, Bacigalupo A, Piaggio G, Figari O, van Lint MT, Occhini D, et al. Severe aplastic anemia (SAA): Response to cyclosporin A (CyA) in vivo and in vitro. Eur J Haematol. 1991;46:212-6.
117. Bitencourt MA, Medeiros CR, Zanis-Neto J, Andrade RJ, Ogasawara VS, Friedrich VLK, et al. Prednisone and cyclosporine for severe acquired aplastic anemia: 101 Cases treated at a single institution (abstract). Blood. 1995;86(suppl 1):476a.
118. Schrezenmeier H, Schlander M, Raghavachar A. Cyclosporin A in aplastic anemia - report of a workshop. Ann Hematol. 1992;65:33-6.
119. Gluckman E, Esperou-Bourdeau H, Baruchel A, Boogaerts M, Briere J, Donadio D, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992;79:2540-6.
120. Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol. 1989;72:278-84.
121. Hinterberger-Fischer M, Hocker P, Lechner K, Seewann H, Hinterberger W. Oral cyclosporine-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure. Eur J Haematol. 1989;43:136-42.
122. Marsh JC, Zomas A, Hows JM, Chapple M, Gordon-Smith EC. Avascular necrosis after treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone. Br J Haematol. 1993;84:731-5.
123. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA Working Party. Br J Haematol. 1988;70:177-82.
124. Stewart FM. Hypoplastic/aplastic anemia. Role of bone marrow transplantation. Med Clin North Am. 1992;76:683-97.
125. Gluckman E, Devergie A, Poros A, Degoulet P. Results of immunosuppression in 170 cases of severe aplastic anaemia. Report of the European Group of Bone Marrow Transplant (EGBMT). Br J Haematol. 1982;51:541-50.
126. Storb R, Champlin RE. Bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant. 1991;8:69-72.
127. Champlin R, Gluckman E, Horowitz M, for the International Bone Marrow Transplant Registry. Effect of immunosuppressive treatment regimen on survival after bone marrow transplantation (BMT) for severe aplastic anemia (abstract). Blood. 1989;74(suppl 1):163a.
128. Storb R, Anasetti C, Appelbaum F, Bensinger W, Buckner CD, Clift R, et al. Marrow transplantation for severe aplastic anemia and thalassemia major. Semin Hematol. 1991;28:235-9.
129. Storb R, Leisenring W, Deeg HJ, Anasetti C, Appelbaum F, Bensinger W, et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia (letter). Blood. 1994;83:2749-50.
130. Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC, et al. Bone marrow transplantation for severe aplastic anemia: Influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992;79:269-75.
131. Anasetti C, Storb R, Longton G, Witherspoon R, Doney K, Sullivan KM, et al. Donor buffy coat cell infusion after marrow transplantation for aplastic anemia (letter). Blood. 1988;72:1099-100.
132. Schuening F, Bean MA, Deeg HJ, Storb R. Prevention of graft failure in patients with aplastic anemia. Bone Marrow Transplant. 1993;12(suppl 3):S48-9.
133. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941-9.
134. Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R, Cosset JM. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: Long-term follow-up. Blood. 1991;78:2451-5.
135. Kurisu K, Hishikawa Y, Taniguchi M, Kamikonya N, Miura T, Kanamaru A, et al. Total lymphoid irradiation and total body irradiation for allogeneic bone marrow transplantation in aplastic anemia. Radiat Med. 1991;9:148-52.
136. Or R, Mehta J, Kapelushnik J, Aker M, Naparstek E, Nagler A, et al. Total lymphoid irradiation, anti-lymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection. Bone Marrow Transplant. 1994;13:97-9.
137. Socie G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood. 1991;78:277-9.
138. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993;329:1152-7.
139. Witherspoon RP, Storb R, Pepe M, Longton G, Sullivan KM. Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone (letter). Blood. 1992;79:289-91.
140. McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: A report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant. 1994;13:233-7.
141. Storb R, Weiden PL, Sullivan KM, Appelbaum FR, Beatty P, Buckner CD, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: Use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood. 1987;70:116-21.
142. Horstmann M, Stockschlader M, Kabisch H, Zander A. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia transplanted with bone marrow from HLA-identical related donors (letter). Blood. 1995;85:1404-5.
143. Bortin MM, Horowitz MM, Rowlings PA, Rimm AA, Sobocinski KA, Zhang MJ, et al. 1993 Progress report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1993;12:97-104.
144. Klingemann H-G, Storb R, Fefer A, Deeg HJ, Appelbaum FR, Buckner CD, et al. Bone marrow transplantation in patients aged 45 years and older. Blood. 1986;67:770-6.
145. Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386-92.
146. Storb R. Bone marrow transplantation for aplastic anemia. Cell Transplant. 1993;2:365-79.
147. Gluckman E, Marmont A, Speck B, Gordon-Smith EC. Immunosuppressive treatment of aplastic anemia as an alternative treatment for bone marrow transplantation. Semin Hematol. 1984;21:11-9.
148. May WS, Sensenbrenner LL, Burns WH, Ambinder R, Carroll MP, Griffin CA, et al. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant. 1993;11:459-64.
149. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461-6.
150. Paquette RL, Tebyani N, Frane M, Ireland P, Ho WG, Champlin RE, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: Comparison with bone marrow transplantation. Blood. 1995;85:283-90.
151. Pierga JY, Socie G, Gluckman E, Devergie A, Henry-Amar M, Bridier A, et al. Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. Radiother Oncol. 1994;30:55-8.
152. Doney K, Pepe M, Storb R, Bryant E, Anasetti C, Appelbaum FR, et al. Immunosuppressive therapy of aplastic anemia: Results of a prospective, randomized trial of anti-thymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. Blood. 1992;79:2566-71.
153. Tichelli A, Gratwohl A, Wursch A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol. 1988;69:413-8.
154. Appelbaum FR, Barrall J, Storb R, Ramberg R, Doney K, Sale GE, et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol. 1987;15:1134-9.
155. Witherspoon RP, Deeg HJ, Storb R. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplant Sci. 1994;4:33-41.
156. Brauer MJ, Dameshek W. Hypoplastic anemia and myeloblastic leukemia following chloramphenicol therapy. Report of three cases. N Engl J Med. 1967;277:1003-5.
157. Cohen T, Creger WP. Acute myoloid leukemia following seven years of aplastic anemia induced by chloramphenicol. Am J Med. 1967;43:762-70.
158. Bacigalupo A, Podesta M, Raffo MR, Piaggio G, Van Lint MT, Vimercati R, et al. Lack of in vitro colony (CFUC) formation and myelosuppressive activity in patients with severe aplastic anemia after autologous hematologic reconstitution. Exp Hematol. 1980;8:795-801.
159. Narayanan MN, Geary CG, Freemont AJ, Kendra JR. Long-term follow-up of aplastic anaemia. Br J Haematol. 1994;86:837-43.
160. Schrezenmeier H, Marin P, Raghavachar A, McCann S, Hows J, Gluckman E, et al. Relapse of aplastic anaemia after immunosuppressive treatment: A report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol. 1993;85:371-7.
161. Loughran TP Jr, Storb R. Treatment of aplastic anemia. Hematol Oncol Clin North Am. 1990;4:559-75.
162. Hows JM. Severe aplastic anaemia: The patient without a HLA-idcntical sibling. Br J Haematol. 1991;77:1-4.
163. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
164. Crump M, Larratt LM, Maki E, Curtis JE, Minden MD, Meharchand JM, et al. Treatment of adults with severe aplastic anemia: Primary therapy with antithymocyte globulin (ATG) and rescue of ATG failures with bone marrow transplantation. Am J Med. 1992;92:596-602.
165. Bayever E, Champlin R, Ho W, Lenarsky C, Storch S, Ladisch S, et al. Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. J Pediatr. 1984;105:920-5.
166. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504-14.
167. French Cooperative Group for the Study of Aplastic and Refractory Anemias. Androgen therapy in aplastic anaemia: A comparative study of high and low-doses and of 4 different androgens. Scandinavian Journal of Haematology. 1986;36:346-52.
168. Antin JH, Smith BR, Holmes W, Rosenthal DS. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood. 1988;72:705-13.
169. Yoshida Y, Okuma M, Suzuki T, Takahashi T, Nakagawa M, Kashima K, et al. A phase III trial of subcutaneous administration of rhG-CSF in aplastic anemia. Rinsho Ketsueki. 1994;35:1282-8.
170. Sonoda Y, Ohno Y, Fujii H, Takahashi T, Nakayama S, Haruyama H, et al. Multilineage response in aplastic anemia patients following long-term administration of filgrastim (recombinant human granulocyte colony stimulating factor). Stem Cells (Dayt). 1993;11:543-54.
171. Nimer SD. The use of colony-stimulating factors in primary hematologic disorders. Cancer. 1992;70(suppl 4):921-7.
172. Kojima S, Fukuda M, Miyajima Y, Matsuyama T, Horibe K. Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor. Blood. 1991;77:937-41.
173. Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herr- mann F, Eder M, et al. Clinical effects of recombinant human interlcukin-3. Am J Clin Oncol. 1991;14(suppl 1):S51-63.
174. Nimer SD, Paquette RL, Ireland P, Resta D, Young D, Golde DW. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol. 1994;22:875-80.
175. Imamura M, Kobayashi M, Kobayashi S, Yoshida K, Mikuni C, Ishikawa Y, et al. Combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in aplastic anemia. Am J Hematol. 1995;48:29-33.
176. Marsh JCW, Secie G, Schrezenmeier H, Tichelli A, Gluckman E, Ljungman P, et al. Haemopoietic growth factors in aplastic anaemia: A cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet. 1994;344:172-3.
177. Hord JD, Gay JC, Whitlock JA, Janco RL, Edwards JR, Greer JP, et al. Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia (abstract). Blood. 1994;84(suppl 1):9a.
178. McKenzie SE, Manno CS, Martin MB, Cohen AR. Combined immunosuppression and growth factor therapy in childhood aplastic anemia (abstract). Blood. 1994;84(suppl 1):10a.
179. Guinan EC, Dunn Lopez K, McKenzie SE, Lobel J, Cohen P, Singer D, et al. Successful treatment (RX) of patients (PTS) with refractory severe aplastic anemia (SAA) with concomitant cyclosporin (CSA) and colony-stimulating factors (CSF) (abstract). Blood. 1994;84(suppl 1):10a.
180. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood. 1996;87:491-4.
181. Deeg HJ, Anasetti C, Petersdorf E, Storb E, Doney K, Hansen JA, et al. Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors (letter). Blood. 1994;83:3417-8.
182. Camitta B, Casper J, Pietryga D, Garbrecht F, Ash R, Keever C, et al. Unrelated donor marrow transplantation (BMT) for children with severe aplastic anemia (AA) (abstract). Blood. 1993;82(suppl):344a.
183. Hows J, Szydlo R, Anasetti C, Camitta B, Gajewski J, Gluckman E. Unrelated donor marrow transplants for severe acquired aplastic anemia. Bone Marrow Transplant. 1992;10(suppl 1):102-6.
184. Wagner JL, Deeg HJ, Seidel K, Anasetti C, Doney K, Sanders J, et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. Transplantation. 1996;61:54-61.